1 The human P2Y 11 receptor is coupled to both the phosphoinositide and the cyclic AMP pathways. A pharmacological characterization of the recombinant human P2Y 11 receptor has been conducted following stable expression in two dierent cell lines: the 1321N1 astrocytoma cells for inositol trisphosphate measurements and the CHO-K1 cells for cyclic AMP assays. The rank order of potency of a series of nucleotides was almost identical for the two pathways: ATPgS&BzATP4 dATP4ATP4ADPbS42MeSATP. 2 ADPbS, AMPaS and A3P5PS behaved as partial agonists of the human P2Y 11 receptor. At high concentrations, these three nucleotides were able to partially inhibit the ATP response. 3 Suramin was a more potent antagonist than reactive blue 2, whereas pyridoxal-phosphate-6-azophenyl-2',4'-disulphonic acid was completely inactive. The P2Y 11 receptor proved to be sensitive to suramin in a competitive way with an apparent K i value of 0.82+0.07 mM. 4 The ATP derivative AR-C67085 (2-propylthio-b, g-dichloromethylene-D-ATP), a potent inhibitor of ADP-induced platelet aggregation, was the most potent agonist of the P2Y 11 receptor, among the various nucleotides tested. 5 The pharmacological pro®le of the recombinant human P2Y 11 receptor is closely similar to that of the cyclic AMP-coupled P 2 receptor recently described in HL-60 cells, suggesting that it is the same receptor.
Introduction
The receptors activated by extracellular nucleotides are called P2 receptors (Burnstock, 1972) . They have been divided in two groups: P2X receptors which are ligand-gated cation channels (Abbracchio & Burnstock, 1994) and P2Y receptors coupled to G proteins (Fredholm et al., 1994) . A large number of subtypes have been cloned for these two families. Inside the P2Y family, the P2Y 1 and P2Y 11 are speci®cally activated by adenine nucleotides (Webb et al., 1993; Communi et al., 1997) . Other subtypes are responsive to uracil nucleotides. Rat and human P2Y 6 receptors, as well as their avian ortholog previously called P2Y 3 (Barnard et al., 1994; Li et al., 1998) , are preferentially activated by UDP (Chang et al., 1995; Communi et al., 1996a) . The human P2Y 4 receptor is a UTP receptor (Communi et al., 1995a; 1996b; Nguyen et al., 1995; Nicholas et al., 1996) , whereas its rat ortholog is activated by both ATP and UTP (Webb et al., 1998; Bogdanov et al., 1998) , like the P2Y 2 and P2Y 8 receptors (Lustig et al., 1993; Bogdanov et al., 1997) . There is no functional evidence at that time that the p2y 5 , p2y 9 and p2y 10 receptors are nucleotide receptors (Li et al., 1997; Janssens et al., 1997) whereas the p2y 7 receptor is de®nitely a leukotriene B 4 receptor (Yokomizo et al., 1997) .
Preliminary pharmacological data have shown that the P2Y 11 receptor is preferentially activated by ATP and is coupled to both the phosphoinositide and the adenylyl cyclase pathways . The coupling of this receptor to adenylyl cyclase stimulation is a unique feature among the P2Y family. The aim of this study was to provide a full characterization of the human P2Y 11 receptor in terms of rank order of potency of a range of nucleotides and sensitivity to antagonists, to detect possible discrepancies between the two signalling pathways and to compare these features to the pharmacological pro®le of the cyclic AMP-linked P 2 receptor recently described on HL-60 leukaemia cells (Conigrave et al, 1998) . That characterization was performed in two distinct cell lines stably expressing the P2Y 11 receptor. Since 1321N1 cells express an adenosine receptor coupled to adenylyl cyclase stimulation, the cyclic AMP experiments were performed in CHO-K1 cells; reciprocally, the inositol phosphate experiments were performed in 1321N1 cells, since CHO-K1 cells have an endogeneous P2Y 2 receptor coupled to phospholipase C (Iredale & Hill, 1993) .
Methods

Materials
Trypsin was from Flow Laboratories (Bioggio, Switzerland). Culture media and foetal bovine serum (FBS) were purchased from GIBCO ± BRL (Grand Island, NY, U.S.A. ) was from Amersham (Ghent, Belgium). Dowex AG1X8 (formate form) was from Bio-Rad Laboratories (Richmond, CA, U.S.A.). ATP, GTP, CTP, TTP, ITP, ATPgS (adenosine 5-O-(3-thiotriphosphate)), ADPbS (adenosine 5'-O-(2-thiodiphosphate)), AMPaS (adenosine 5'-O-thiomonophosphate), BzATP (2'-and 3'-O-(4-benzoyl-benzoyl)adenosine 5'-triphosphate), A2P5P (adenosine 2',5'-diphosphate), A3P5P (adenosine 3',5'-diphosphate), A3P5PS (adenosine 3'-phosphate 5'-phosphosulphate), the diadenosine polyphosphates (AP 4 A, AP 5 A and AP 6 A) and pertussis toxin were obtained from Sigma Chemical Co. (St. Louis, MO, U.S.A.). Indomethacin was from Merck. 2-Methylthio-ATP (2MeSATP), suramin, reactive blue 2 (RB-2), pyridoxal-phosphate-6-azophenyl-2',4'-disulphonic acid (PPADS) and 8-(p-sulphophenyl)theophylline (8-p-SPT) were from Research Biochemicals International (Natick, MA, U.S.A.). Rolipram was a gift from the Laboratoires Jacques Logeais (Trappes, France). AR-C67085 (2-propylthio-b, gdichloromethylene-D-ATP) was a generous gift of Drs J.D. Turner and P. Le (Astra Charnwood). Table 1 were determined by curve ®tting (Sigma plot: version 2.0).
Cell culture and transfection
The 1321N1 and CHO-K1 cells transfected with the P2Y 11 -pEFIN3 recombinant vector as previously described . The incubation was stopped by the addition of an ice cold 3% perchloric acid solution. Inositol phosphates were extracted and separated on Dowex columns as previously described (Communi et al., 1995b) . EC 50 and IC 50 values were obtained by curve ®tting (Sigma plot: version 2.0). Slope and pA 2 values were obtained from a linear regression of a Schild plot analysis (Sigma plot: version 2.0).
Cyclic AMP measurements
CHO-K1 transfected cells were spread on Petri dishes (150,000 cells/35-mm dish) and cultured in Ham's F12 medium containing 10% FCS, antibiotics, amphotericin, sodium pyruvate and 400 mg ml 71 G418. Cells were then preincubated for 30 min in KRH buer with 25 mM rolipram and incubated in the same medium for dierent times in the presence of the agonists and in the presence or the absence of various antagonists (15 min in most experiments). The incubation was stopped by the addition of 1 ml HCl 0.1 M. The incubation medium was dried up, resuspended in water and diluted as required. Cyclic AMP was quanti®ed by radioimmunoassay after acetylation as previously described (Brooker et al., 1979) . EC 50 and IC 50 values were obtained by curve ®tting (Sigma plot: version 2.0).
Results
We have ®rst studied the time course of the ATP response ( Figure 1A ,B). The IP 3 response reached a ®rst peak after 1 min, but the response was already signi®cant after 15 s. The response was maintained and even increased at longer times (1 h), despite the absence of lithium. We have chosen 30 s as stimulation time for all the following experiments in order to minimize agonist degradation. Concerning the time course of cyclic AMP production, the ATP response was already signi®cant after 1 min: increase from 0.4 to 3 pmoles. The half-maximum response was obtained at 5 min. We have chosen 15 min as stimulation time for all the following experiments.
We have then tested the eect of a series of nucleotides on the accumulation of both IP 3 and cyclic AMP ( Figure  2A,B) . The rank order of agonist potency was almost identical for the two pathways: ATPgS&BzATP4dAT-P4ATP4ADPbS42MeSATP (Table 1 ). The only dier- ence was that ATPgS was slightly more potent than BzATP to stimulate the cyclic AMP pathway, whereas the opposite was true for the phosphoinositide pathway. In CHO-K1 cells, ADPbS and AMPaS clearly behaved as partial agonists of the P2Y 11 receptor and had a lower potency than ATP itself ( Figure 3B ). At a concentration of 300 mM, where the cyclic AMP response had reached a plateau, the eects of ADPbS and AMPaS represented respectively 70+7% and 63+16% of the ATP response (mean+s.d. of three independent experiments). This could not be evaluated in the 1321N1 cells, since a plateau was not reached even at a 1 mM concentration of these nucleotides ( Figure 3A ). We have then tested the potential inhibitory eect of these two thiophosphorylated agonists on the ATP response (Figure 4) . At a concentration of 1 mM ADPbS or AMPaS, an inhibition of respectively 35+5% and 56+6% of the IP 3 response induced by ATP 100 mM was observed (mean+s.d. of three independent experiments). These inhibitions have been reproduced on the cyclic AMP pathway but they were observed at higher concentrations: 19+4% inhibition for ADPbS 3 mM and 37+6% for AMPaS 3 mM (mean+s.d. of three independent experiments).
We have also tested three known nucleotide antagonists of the human P2Y 1 receptor (Boyer et al., 1996) : A2P5P, A3P5P and A3P5PS (Figure 5A ,B). A2P5P and A3P5P had no signi®cant eect on the P2Y 11 receptor. At a concentration of 300 mM, the A3P5PS IP 3 response represented 24+8% of the maximal ATP response and A3P5PS was able to produce a 37+9% inhibition of the ATP response ( Figure 5A ) (mean s.d. of three independent experiments). A signi®cant eect of A3P5PS was also observed at lower concentrations on the cyclic AMP response ( Figure 5B ). A3P5PS behaved as an agonist of the P2Y 11 receptor with a maximal eect representing 78+4% of the maximal ATP response and with an EC 50 of 61+5 mM (mean+s.d. of three independent experiments). At a concentration of 1 mM, A3P5PS produced an inhibition of 20+4% of the response to ATP 100 mM, consistent with its partial agonist nature ( Figure 5B ) (mean+s.d. of three independent experiments).
A series of non-adenine triphosphonucleotides (UTP, GTP, CTP, TTP, ITP) and several diadenosine polyphosphates (AP 4 A, AP 5 A, AP 6 A) were completely unable to activate the P2Y 11 receptor, as evaluated both by IP 3 and cyclic AMP measurements (data not shown).
We have then tested the eect of three non-speci®c antagonists which have already been used to discriminate some P 2 receptors : suramin, RB-2 and PPADS (Boyer et al., 1994; Brown et al., 1995) . PPADS had no eect on IP 3 nor on cyclic AMP (data not shown). On the contrary, suramin and RB-2 were able to produce a full inhibition of the IP 3 accumulation induced by ATP. Suramin was the most potent antagonist ( Figure 6A ) (IC 50 (suramin)=1.00+0.07 mM and IC 50 (RB-2)=9.0+1.3 mM; mean+s.d. of three independent experiments). Suramin produced a complete inhibition of the cyclic AMP response, with an IC 50 of 16.0+4.2 mM (mean+s.d. of three independent experiments); with RB-2, the inhibition of the cyclic AMP response to ATP was incomplete and reached a maximum of 51+3% ( Figure 6B ) (mean+s.d. of three independent experiments). This apparently partial inhibitory eect is explained by the observation that high concentrations of RB-2 increase per se the cyclic AMP level in CHO-K1 cells expressing the P2Y 11 receptor ( Figure 6B ), as well as in non-transfected CHO-K1 and 1321N1 cells (data not shown). We have then tested the eect of various concentrations of suramin on the ATP concentration-action curve ( Figure 7A ). Each suramin concentration generated a shift in the curves to the right without aecting the maximum eect of ATP. A linear Schild plot has been derived from these data: it was characterized by a slope of 0.81+0.10 and a K i value of 0.82+0.07 mM (pA 2 =6.09+0.52) (mean+s.d. of three independent experiments) ( Figure 7B ).
We have also tested AR-C67085, an ATP analogue known to inhibit ADP-induced platelet aggregation. Not only had AR-C67085 no antagonist activity, but, among the nucleotides tested, it proved to be the most potent agonist of the P2Y 11 receptor. The EC 50 values of AR-C67085 for IP 3 and cyclic AMP accumulation were respectively 8.9+1.2 mM and 1.5+0.4 mM, as compared to respectively 72+8 mM and 17.4+6.1 mM for ATP (mean+s.d. of three independent experiments) (Figure 8) .
Pretreatment of the cells with 50 ng ml 71 pertussis toxin during 24 h had no eect on the IP 3 formation induced by ATP (data not shown). To exclude the possibility that the cyclic AMP response to ATP was a consequence of prostaglandins release due to an increase in the intracellular Ca 2+ concentration, we have tested the eect of a preincubation of the cells with indomethacin (10 mg ml 71 ) during 30 min. There was no eect on the cyclic AMP response induced by ATP 30 mM. 8-p-SPT (100 mM), an antagonist of adenosine receptors, was also unable to inhibit this response (data not shown).
Discussion
The pharmacological characterization of the human P2Y 11 receptor has been conducted in two dierent cell lines. We have chosen the 1321N1 astrocytoma cells to perform inositol trisphosphate measurements and the CHO-K1 cells to perform cyclic AMP assays. Indeed, a signi®cant endogeneous cyclic AMP response to adenosine, a degradation product of ATP, is obtained in the 1321N1 cells. When this endogeneous response to adenosine was inhibited by 8-p-SPT, a signi®cant cyclic AMP response to ATP was still observed, but only at high concentrations (300 mM), suggesting that the coupling of the P2Y 11 receptor to adenylyl cyclase has a low ecacy in the 1321N1 cell line (data not shown). This is entirely consistent with the data reported by Kennedy et al. (1999) . Therefore we did not perform a characterization of the cyclic AMP response to ATP and its derivatives in the 1321N1 cell line. By contrast, the CHO-K1 cells do not possess adenosine receptors coupled to adenylyl cyclase, but they express an endogeneous P2Y 2 receptor coupled to the phosphoinositide pathway and which presents a high anity for ATP (Iredale & Hill, 1993) . Following transfection by the P2Y 11 receptor, the inositol phosphate response to ATP was not signi®cantly enhanced, indicating that this model is not adequate to characterize the coupling of the P2Y 11 receptor to phospholipase C.
The time course of IP 3 accumulation is particularly sustained in the absence of lithium. This suggests a lack of desensitization of this receptor like it was observed for the P2Y 6 receptor transfected in the same cell line (Robaye et al., 1997) . This receptor was also coupled to a pertussis toxininsensitive G protein. The time course of cyclic AMP accumulation was slower but compatible with a direct coupling to a G s protein. Indeed the TSH receptor, which is a typical G scoupled receptor, displayed a similar time course of cyclic AMP accumulation, when expressed in the same cell line and using the same phosphodiesterase inhibitor Rolipram (Perret et al., 1990 ).
There was no major dierence in agonist or antagonist sensitivity between the two signalling pathways. The only discrepancy was that ATPgS was the most potent agonist to stimulate the cyclic AMP pathway, whereas BzATP was the most potent on IP 3 . Since cyclic AMP experiments lasted for 15 min, this dierence is likely to re¯ect the resistance of ATPgS to hydrolysis by ectonucleotidases. EC 50 of agonists were consistently lower in CHO-K1 cells, while the IC 50 of antagonists were higher. This could be explained if the level of receptor expression was higher in the CHO-K1 cells, thus providing a larger receptor reserve. It is important to note that the nucleotides have been used without any previous HPLCpuri®cation and that it could have some relevance to long time stimulation like in the cyclic AMP assays.
The hypothesis that the P2Y 11 receptor could be coupled to additional signaling pathways, possibly activated at lower ATP concentrations than phospholipase C and adenylyl cyclase stimulation, was investigated. No evidence of P2Y 11 receptor coupling to adenylyl cyclase inhibition, phospholipase A 2 activation (measured by the release of arachidonate) or phospholipase D activation (measured by the release of choline) could be obtained (data not shown).
The observation that AR-C67085 is the most potent agonist of the P2Y 11 receptor was unexpected, since so far this compound was considered to be a highly selective antagonist of the platelet ADP receptor coupled to adenylyl cyclase inhibition and platelet aggregation (Humphries et al., 1995) . Although this compound was approximately 10 fold more potent than ATP itself, it must be underscored that its potency at the platelet receptor is several orders of magnitude higher than at the P2Y 11 receptor.
The P2Y 11 subtype was sensitive to suramin antagonism. Suramin behaved clearly as a competitive antagonist of the P2Y 11 receptor with a low K i value as compared to its eect on other P2Y receptors, except for the P2Y 1 receptor. The pA 2 value was indeed 6.09 for the P2Y 11 receptor, as compared to 5.77 for the P2Y 1 subtype and 4.32 for the P2Y 2 one (Charlton et al., 1996) . In addition, suramin is a weak antagonist of the P2Y 6 receptor (Robaye et al., 1997) and is inactive on the P2Y 4 receptor (Communi et al., 1996b) .
Northern blotting experiments have demonstrated the expression of the P2Y 11 receptor in the HL-60 human promyelocytic leukaemia cell line . The existence of a cyclic AMP-linked P2 receptor mediating the granulocytic dierentiation of these cells has also been reported recently (Jiang et al., 1997) . The present pharmacological characterization strongly supports that the P2Y receptor coupled to the cyclic AMP pathway in these cells is in fact the P2Y 11 receptor. Indeed, a lot of pharmacological features of the P2Y receptor coupled to the cyclic AMP pathway in HL-60 cells (Jiang et al., 1997; Choi & Kim, 1997; Conigrave et al., 1998) are similar to those of the recombinant P2Y 11 receptor. The most striking similarity was the rank order of potency of agonists, with ATPgS, BzATP and dATP being more potent than ATP itself. Moreover ADPbS and AMPaS behaved as partial agonists, able to partially inhibit the ATP response, in both systems. Finally, the sensitivity of the recombinant P2Y 11 receptor to suramin is consistent with the observation that 100 mM suramin completely blocked the eect of 300 mM ATP in HL-60 cells (Choi & Kim, 1997) . In conclusion our previous demonstration by Northern blotting that P2Y 11 receptor mRNA is present in HL-60 cells, together with the functional similarities between the cyclic AMP responses triggered by ATP in HL-60 cells and in CHO-K1 cells expressing the human P2Y 11 receptor observed in the present study, strongly suggest that this receptor is involved in the granulocytic dierentiation of HL-60 cells by ATP (Jiang et al., 1997; Conigrave et al., 1998) .
